Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Feb;27(2):203–206. doi: 10.1128/aac.27.2.203

Ineffectiveness and toxicity of BCG vaccine for the prevention of recurrent genital herpes.

J M Douglas, L A Vontver, W E Stamm, W C Reeves, C Critchlow, M L Remington, K K Holmes, L Corey
PMCID: PMC176238  PMID: 3885848

Abstract

One hundred fifty-five patients with genital herpes were enrolled in a double-blind, placebo-controlled trial comparing 0.1 ml of intradermal BCG vaccine with placebo for the prevention of recurrent episodes of genital herpes. The mean rate or recurrence over 9 months of prospective follow-up was 0.528 recurrences per month in BCG recipients compared with 0.392 recurrences per month in placebo recipients (not significant). The BCG vaccine also failed to influence the duration of lesions in the first recurrent episode of genital herpes after vaccination. Six patients were given a second inoculation of BCG vaccine, and persistent cutaneous granulomas were noted in three of these six patients. Intradermal inoculation with BCG does not appear to affect the natural history of genital herpes, and repeated inoculations can be toxic.

Full text

PDF
203

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson F. D., Ushijima R. N., Larson C. L. Recurrent herpes genitalis. Treatment with Mycobacterium bovis (BCG). Obstet Gynecol. 1974 Jun;43(6):797–805. [PubMed] [Google Scholar]
  2. Aungst C. W., Sokal J. E., Jager B. V. Complications of BCG vaccination in neoplastic disease. Ann Intern Med. 1975 May;82(5):666–669. doi: 10.7326/0003-4819-82-5-666. [DOI] [PubMed] [Google Scholar]
  3. Baker M. B., Larson C. L., Ushijima R. N., Anderson F. D. Resistance of female mice to vaginal infection induced by Herpesvirus hominis type 2: effects of immunization with Mycobacterium bovis, intravenous injection of specific Herpesvirus hominis type 2 antiserum, and a combination of these procedures. Infect Immun. 1974 Dec;10(6):1230–1234. doi: 10.1128/iai.10.6.1230-1234.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bast R. C., Jr, Zbar B., Borsos T., Rapp H. J. BCG and cancer. N Engl J Med. 1974 Jun 27;290(26):1458–1469. doi: 10.1056/NEJM197406272902605. [DOI] [PubMed] [Google Scholar]
  5. Benjamin D. R. Use of immunoperoxidase for rapid diagnosis of mucocutaneous herpes simplex virus infection. J Clin Microbiol. 1977 Dec;6(6):571–573. doi: 10.1128/jcm.6.6.571-573.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bierman S. M. BCG immunoprophylaxis of recurrent herpes progenitalis. Arch Dermatol. 1976 Oct;112(10):1410–1415. [PubMed] [Google Scholar]
  7. Brown C. A., Brown I. N., Sljivić V. S. Suppressed or enhanced antibody responses in vitro after BCG treatment of mice: importance of BCG viability. Immunology. 1979 Nov;38(3):481–488. [PMC free article] [PubMed] [Google Scholar]
  8. Corey L., Adams H. G., Brown Z. A., Holmes K. K. Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med. 1983 Jun;98(6):958–972. doi: 10.7326/0003-4819-98-6-958. [DOI] [PubMed] [Google Scholar]
  9. Klimpel G. R., Henney C. S. BCG-induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T cell generation in vitro. J Immunol. 1978 Feb;120(2):563–569. [PubMed] [Google Scholar]
  10. Mackaness G. B., Auclair D. J., Lagrange P. H. Immunopotentiation with BCG. I. Immune response to different strains and preparations. J Natl Cancer Inst. 1973 Nov;51(5):1655–1667. doi: 10.1093/jnci/51.5.1655. [DOI] [PubMed] [Google Scholar]
  11. Muller S. A., Herrmann E. C., Jr, Winkelmann R. K. Herpes simplex infections in hematologic malignancies. Am J Med. 1972 Jan;52(1):102–114. doi: 10.1016/0002-9343(72)90012-5. [DOI] [PubMed] [Google Scholar]
  12. Reeves W. C., Corey L., Adams H. G., Vontver L. A., Holmes K. K. Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. N Engl J Med. 1981 Aug 6;305(6):315–319. doi: 10.1056/NEJM198108063050604. [DOI] [PubMed] [Google Scholar]
  13. Wentworth B. B., Bonin P., Holmes K. K., Gutman L., Wiesner P., Alexander E. R. Isolation of viruses, bacteria and other organisms from venereal disease clinic patients: methodology and problems associated with multiple isolations. Health Lab Sci. 1973 Apr;10(2):75–81. [PubMed] [Google Scholar]
  14. Whitley R. J., Nahmias A. J., Visintine A. M., Fleming C. L., Alford C. A. The natural history of herpes simplex virus infection of mother and newborn. Pediatrics. 1980 Oct;66(4):489–494. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES